[HTML][HTML] Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study
H Li, N Xiong, C Li, Y Gong, L Liu, H Yang… - International Journal of …, 2021 - Elsevier
H Li, N Xiong, C Li, Y Gong, L Liu, H Yang, X Tan, N Jiang, Q Zong, J Wang, Z Lu, X Yin
International Journal of Infectious Diseases, 2021•ElsevierObjective To assess the efficacy and safety of ribavirin and interferon-α (RBV/IFN-α) therapy
in COVID-19 patients. Methods A multicenter, retrospective cohort study of COVID-19
patients admitted to 4 hospitals in Hubei Province, China, from 31 December 2019 to 31
March 2020. Patients were divided into 2 groups according to their exposure to RBV/IFN-α
therapy within 48 h of admission. Mixed-effect Cox model and Logistic regression were used
to explore the association between early treatments of RBV/IFN-α and primary outcomes …
in COVID-19 patients. Methods A multicenter, retrospective cohort study of COVID-19
patients admitted to 4 hospitals in Hubei Province, China, from 31 December 2019 to 31
March 2020. Patients were divided into 2 groups according to their exposure to RBV/IFN-α
therapy within 48 h of admission. Mixed-effect Cox model and Logistic regression were used
to explore the association between early treatments of RBV/IFN-α and primary outcomes …
Objective
To assess the efficacy and safety of ribavirin and interferon-α (RBV/IFN-α) therapy in COVID-19 patients.
Methods
A multicenter, retrospective cohort study of COVID-19 patients admitted to 4 hospitals in Hubei Province, China, from 31 December 2019 to 31 March 2020. Patients were divided into 2 groups according to their exposure to RBV/IFN-α therapy within 48 h of admission. Mixed-effect Cox model and Logistic regression were used to explore the association between early treatments of RBV/IFN-α and primary outcomes.
Results
Of 2037 patients included, 1281 received RBV/IFN-α (RBV, IFN-α or RBV combined with IFN-α) treatments and 756 received none of these treatments. In a mixed effect model, RBV/IFN-α therapy was not associated with progression from non-severe into severe type (adjusted hazard ratio (aHR) = 1.09, 95% CI: 0.88−1.36) or with reduction in 30-day mortality (aHR = 0.89, 95% CI: 0.61−1.30). However, it was associated with a higher probability of hospital stay >15 days (adjusted odds ratio (aOR) = 2.11, 95% CI: 1.68−2.64) compared with no RBV/IFN-α therapy. The propensity score-matched cohort and subgroup analysis displayed similar results.
Conclusion
RBV/IFN-α therapy was not observed to improve clinical outcomes in COVID-19 patients suggesting that RBV/IFN-α therapy should be avoided in COVID-19 treatment.
Elsevier